中枢神经系统瘤中的BRAF突变-预后标记物和治疗点
Thiago P Muniz1, Warren P Mason2
1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. thiago.muniz@uhn.ca.
CNS drugs
|June 2, 2023
概括
针对性BRAF V600E疗法在质瘤方面表现有前途. 基因组导向治疗改善了复发性/耐药性质瘤的结果,突出了全面基因组评估的必要性.
科学领域:
- 神经瘤学神经瘤学
- 分子瘤学分子瘤学
- 基因组学就是基因组学.
背景情况:
- 质瘤是多样化的脑瘤,治疗选择很少.
- BRAF V600E突变为个性化质瘤治疗提供了一个目标.
研究的目的:
- 审查BRAF V600E在质瘤发展中的作用.
- 描述相关的基因组变化及其预后影响.
- 评估BRAF抑制剂在质瘤中的有效性和毒性.
主要方法:
- 关于BRAF V600E在质生成中的综合文献综述.
- 对BRAF抑制剂疗效和毒性数据的分析.
- 检查耐药机制和未来的治疗策略.
主要成果:
- BRAF V600E突变是质瘤的一个子集的关键驱动因素.
- 包括BRAF和MEK抑制剂在内的向疗法在耐火性/复发性质瘤中显示出有效性.
- 确定了毒性概况和耐药性机制.
结论:
- 基因组导向疗法为质瘤患者提供了更好的结果.
- 综合的基因组分析对管理难以治疗的质瘤至关重要.
- 需要进一步的临床试验来评估一线和克服耐药性的向疗法.
更多相关视频
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
6.1K
06:44Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
Published on: March 1, 2024
1.1K
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
